Paraproteinaemic neuropathy: MGUS and beyond.

Autor:	Carroll AS; Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.; National Hospital for Neurology and Neurosurgery, London, UK., Lunn MPT; National Hospital for Neurology and Neurosurgery, London, UK michaellunn@nhs.net.
Jazyk:	angličtina
Zdroj:	Practical neurology [Pract Neurol] 2021 Dec; Vol. 21 (6), pp. 492-503. Date of Electronic Publication: 2021 Jul 19.
DOI:	10.1136/practneurol-2020-002837
Abstrakt:	Paraproteinaemic neuropathies comprise a heterogeneous group of neuro-haematological conditions with some distinct neurological, haematological and systemic phenotypes. The spectrum of disease varies from mild to severe, indolent to rapidly progressive and from small fibre sensory involvement to dramatic sensorimotor deficits. The haematological association may be overlooked, resulting in delayed treatment, disability, impaired quality of life and increased mortality. However, the presence of an irrelevant benign paraprotein can sometimes lead to inappropriate treatment. In this review, we outline our practical approach to paraproteinaemic disorders, discuss the utility and limitations of diagnostic tests and the distinctive clinical phenotypes and touch on the complex multidisciplinary management approaches. Competing Interests: Competing interests: ASC and MPTL received no funding or sponsorship for this commissioned paper. MPTL Consultancy: UCB Pharma, CSL Behring and Polyneuron. PI on trials with Polyneuron and UCB Pharma for which his institution receives investigator fees. DSMB: Octapharma, IoC trial, AstraZeneca Pharmaceuticals. (© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu